



### Important Dates

Meeting dates: December 3-8, 2020

### ASH News

**Michelle M. Le Beau**, PhD, Arthur and Marian Edelstein Professor of Medicine and director of the University of Chicago Medicine Comprehensive Cancer Center, will receive the 2020 Henry M. Stratton Medal from the American Society of Hematology (ASH) for her contributions to basic research. The medal, one of the cancer field's top honors, recognizes investigators who have made well-recognized contributions to hematology research. Read the UCCCC article [here](#), and the ASH announcement [here](#).

**Wendy Stock**, MD, Anjuli Seth Nayak Professor of Medicine, will receive the 2020 Clinical Mentor Award for contributing to the professional development of numerous hematology trainees at various stages in her career. Read the ASH announcement [here](#).

Jovian Yu, MD, second year fellow in the lab of **Justin Kline**, MD, was selected to receive an ASH Abstract Achievement Award for the submission: "Single-Cell Analysis of the Classical Hodgkin Lymphoma Immune Environment Reveals a Clonally-Expanded CD8+T Cell Population with a Cytotoxic Phenotype".

Anand Patel, MD, fellow in the department of hematology/oncology, was selected to receive an ASH Abstract Achievement Award for the submission: "Expanding Use of a Modified Pediatric Intensive Regimen for Acute Lymphoblastic Leukemia (ALL) into an Older Adult Population: Feasibility and Efficacy Results".

### Sessions, Presentations, and Abstracts

*(Note that **bold names indicate UCCCC Members**, and underlined means affiliated with University of Chicago; Ordered by session number)*

### Thursday, December 3, 2020

Blood Drop: Special Interest

**Result Type:** Session

**Program:** ASH-a-Palooza

# #ASH20

**Presenter:** Lucy Godley

**Time and Location:** Thursday, December 3, 2020: 7:15 AM–7:55 AM; 8:45 AM–9:25 AM

[Blood Buddies: Adult Clinical Malignant Hematology](#)

**Result Type:** Session

**Program:** ASH-a-Palooza

**Presenter:** Olatoyosi Odenike

**Time and Location:** Thursday, December 3, 2020: 10:00 AM–12:00 PM

[Germline Curation – Worked Examples](#)

**Result Type:** Paper

**Presenter:** [Simone Feurstein](#)

**Program:** Scientific Workshops @ ASH

**Session:** Variant Curation: How Should We Interpret What We Find?

**Time and Location:** Thursday, December 3, 2020: 3:24 PM–4:19 PM

## **Friday, December 4, 2020**

[Blood Drop: Hemostasis and Thrombosis](#)

**Result Type:** Session

**Program:** ASH-a-Palooza

**Presenter:** [Radhika Peddinti](#)

**Time and Location:** Friday, December 4, 2020: 7:15 AM–7:55 AM Channel 7; 8:45 AM–9:25 AM Channel 11

[Blood Buddies: Adult Clinical Malignant Hematology](#)

**Result Type:** Session

**Program:** ASH-a-Palooza

**Presenter:** Wendy Stock

**Time and Location:** Friday, December 4, 2020: 10:00 AM–12:00 PM

[Blood Buddies: Pediatric Clinical Malignant Hematology](#)

**Result Type:** Session

**Program:** ASH-a-Palooza

**Presenter:** Tara Henderson

**Time and Location:** Friday, December 4, 2020: 10:00 AM–12:00 PM

[Blood Buddies: Pediatric Clinical Malignant Hematology](#)

**Result Type:** Session

**Program:** ASH-a-Palooza

**Presenter:** Jennifer McNeer

**Time and Location:** Friday, December 4, 2020: 10:00 AM–12:00 PM

# #ASH20

**Saturday, December 5, 2020**

[Distinct Genetic Pathways Define Leukemia Predisposition Versus Adaptive Clonal Hematopoiesis in Shwachman–Diamond Syndrome](#)

**Result Type:** Paper

**Number:** 254

**Presenter:** Alyssa Kennedy

A Kennedy...**Wendy Stock**...C Lindsley.

**Program:** Oral and Poster Abstracts

**Session:** 508. Bone Marrow Failure: Advancing Our Biologic Understanding in Inherited and Acquired Bone Marrow Failure Disorders

**Time and Location:** Saturday, December 5, 2020: 2:00 PM–3:30 PM; Channel 18

[RNA Cytosine Methyltransferases NSUN1 and NSUN2 Mediate the Lineage–Associated Resistance to Venetoclax in Leukemia](#)

**Result Type:** Paper

**Number:** 964

**Presenter:** Shaun Wood

S Wood...**Jason Cheng**.

**Program:** Oral and Poster Abstracts

**Session:** 604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: Poster I

**Time and Location:** Saturday, December 5, 2020: 7:00 AM–3:30 PM; Poster Hall

[Preliminary Results of Balli-01: A Phase I Study of UCART22 \(allogeneic engineered T-cells expressing anti-CD22 Chimeric Antigen Receptor\) in Adult Patients with Relapsed or Refractory \(R/R\) CD22+ B-Cell Acute Lymphoblastic Leukemia \(B-ALL\)](#)

**Result Type:** Paper

**Number:** 163

**Presenter:** Nitin Jain

N Jain...**Hongtao Liu**...**Richard Larson**.

**Program:** Oral and Poster Abstracts

**Session:** 614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Chimeric Antigen Receptor T Cell Therapy

**Time and Location:** Saturday, December 5, 2020: 12:00 PM–1:30 PM; Channel 13

[Efficacy and Safety of Tisagenlecleucel in Adult Patients with Relapsed/Refractory Follicular Lymphoma: Interim Analysis of the Phase 2 Elara Trial](#)

**Result Type:** Paper

**Number:** 1149

**Presenter:** Nathan Fowler

N Fowler...**Peter Riedell**...C Thieblemont.

**Program:** Oral and Poster Abstracts

# #ASH20

**Session:** 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster I

**Time and Location:** Saturday, December 5, 2020: 7:00 AM–3:30 PM; Poster Hall

[A Phase I Study of Anti-ICOS Antibody MEDI-570 for Relapsed/Refractory \(R/R\) Peripheral T-Cell Lymphoma \(PTCL\) and Angioimmunoblastic T-Cell Lymphoma \(AITL\) \(NCI-9930\)](#)

**Result Type:** Paper

**Number:** 1151

**Presenter:** Julio Chavez

J Chavez...**Sonali Smith**...L Siu.

**Program:** Oral and Poster Abstracts

**Session:** 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Poster I

**Time and Location:**

Saturday, December 5, 2020: 7:00 AM–3:30 PM; Poster Hall

[Effect of Age on the Efficacy and Safety of Single Agent Oral Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma \(DLBCL\): A Post-Hoc Analysis of the Sadal Pivotal Study](#)

**Result Type:** Paper

**Number:** 1201

**Presenter:** Marie Maerevoet

M Schuster...**Sonali Smith**...M Maerevoet.

**Program:** Oral and Poster Abstracts

**Session:** 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: Poster I

**Time and Location:** Saturday, December 5, 2020: 7:00 AM–3:30 PM; Poster Hall

[Phase I/II Clinical Trial of Temsirolimus and Lenalidomide in Patients with Relapsed and Refractory Lymphomas](#)

**Result Type:** Paper

**Number:** 1189

**Presenter:** Ajay Major

[Ajay Major](#), Justin Kline, Theodore Karrison...**Sonali Smith**.

**Program:** Oral and Poster Abstracts

**Session:** 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: Poster I

**Time and Location:** Saturday, December 5, 2020: 7:00 AM–3:30 PM; Poster Hall

[Myc Expression and Tumor-Infiltrating T Cells Are Associated with Response in Patients \(Pts\) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma \(r/r DLBCL\) Treated with Tisagenlecleucel in the Juliet Trial](#)

**Result Type:** Paper

**Number:** 1194

**Presenter:** Ulrich Jaeger

# #ASH20

U Jaeger, **Michael Bishop**...P Corradini.

**Program:** Oral and Poster Abstracts

**Session:** 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: Poster I

**Time and Location:** Saturday, December 5, 2020: 7:00 AM–3:30 PM; Poster Hall

[Favorable Overall Survival with Imetelstat Treatment Correlates with Other Clinical Benefits in Intermediate 2 or High Risk Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitor](#)

**Result Type:** Paper

**Number:** 53

**Presenter:** John Mascarenhas

J Mascarenhas...**Olatoyosi Odenike**...J Kiladijian.

**Program:** Oral and Poster Abstracts

**Session:** 634. Myeloproliferative Syndromes: Clinical: New Therapies and JAKi-based Combinations for Myelofibrosis

**Time and Location:** Saturday, December 5, 2020: 7:30 AM–9:00 AM; Channel 15

[Clinical Efficacy and Safety of Oral Decitabine/Cedazuridine in 133 Patients with Myelodysplastic Syndromes \(MDS\) and Chronic Myelomonocytic Leukemia \(CMML\)](#)

**Result Type:** Paper

**Number:** 1230

**Presenter:** Michael Savona

M Savona...**Olatoyosi Odenike**...G Garcia-Manero.

**Program:** Oral and Poster Abstracts

**Session:** 637. Myelodysplastic Syndromes—Clinical Studies: Poster I

**Time and Location:** Saturday, December 5, 2020: 7:00 AM–3:30 PM; Poster Hall

[Correlation Analyses of Imetelstat Exposure with Pharmacodynamic Effect, Efficacy and Safety in a Phase 2 Study in Patients with Higher-Risk Myelofibrosis Refractory to Janus Kinase Inhibitor Identified an Optimal Dosing Regimen for Phase 3 Study](#)

**Result Type:** Paper

**Number:** 1283

**Presenter:** John Mascarenhas

J Mascarenhas...**Olatoyosi Odenike**...J Kiladijian

**Program:** Oral and Poster Abstracts

**Session:** 637. Myelodysplastic Syndromes—Clinical Studies: Poster I

**Time and Location:** Saturday, December 5, 2020: 7:00 AM–3:30 PM; Poster Hall

[Selinexor Efficacy and Safety Are Independent of Renal Function in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma \(DLBCL\): A Post-Hoc Analysis from the Pivotal Phase 2b Sadal Study](#)

**Result Type:** Paper

**Number:** 1384

**Presenter:** Jason Westin

# #ASH20

M Schuster...**Sonali Smith**...M Maerevoet.

**Program:** Oral and Poster Abstracts

**Session:** 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Poster I

**Time and Location:** Saturday, December 5, 2020: 7:00 AM–3:30 PM; Poster Hall

[Patient Expectations and Perceptions of Treatment in CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucl in Relapsed/Refractory Multiple Myeloma](#)

**Result Type:** Paper

**Number:** 1412

**Presenter:** Adam Cohen

A Cohen...**Andrzej Jakubowiak**, S Jagannath.

**Program:** Oral and Poster Abstracts

**Session:** 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Poster I

**Time and Location:** Saturday, December 5, 2020: 7:00 AM–3:30 PM; Poster Hall

[Daratumumab \(DARA\) Plus Carfilzomib, Pomalidomide, Dexamethasone \(Kpd\) in Lenalidomide Refractory Multiple Myeloma \(MM\): A Multi-Center MMRC Study](#)

**Result Type:** Paper

**Number:** 1397

**Presenter:** Jagoda Jasielec

J Jasielec...**Benjamin Derman**...**Andrzej Jakubowiak**.

**Program:** Oral and Poster Abstracts

**Session:** 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Poster I

**Time and Location:** Saturday, December 5, 2020: 7:00 AM–3:30 PM; Poster Hall

[Updated Results from the Phase I CRB-402 Study of Anti-Bcma CAR-T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma: Correlation of Expansion and Duration of Response with T Cell Phenotypes](#)

**Result Type:** Paper

**Number:** 130

**Presenter:** Melissa Alsina

M Alsina...**Andrzej Jakubowiak**...J Berdeja.

**Program:** Oral and Poster Abstracts

**Session:** 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: CAR T Therapies for Myeloma: Novel Approaches and Longer-Term Follow Up Data

**Time and Location:** Saturday, December 5, 2020: 9:30 AM–11:00 AM; Channel 10

[CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucl, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma](#)

**Result Type:** Paper

**Number:** 177

**Presenter:** Deepu Madduri

D Madduri...**Andrzej Jakubowiak**...T Martin.

**Program:** Oral and Poster Abstracts

# #ASH20

**Session:** 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Novel Therapies Targeting B Cell Maturation Antigen in Relapsed/Refractory Multiple Myeloma

**Time and Location:** Saturday, December 5, 2020: 12:00 PM–1:30 PM; Channel 10

[Phase I Trial of a Novel Conditioning Regimen Utilizing Total Marrow Irradiation \(TMI\) with Fludarabine–Melphalan for Patients with Relapsed Hematologic Malignancies Undergoing Second Allogeneic Stem Cell Transplantation \(Allo–SCT\)](#)

**Result Type:** Paper

**Number:** 191

**Presenter:** Hongtao Liu

Hongtao Liu, Bulent Aydogan...[Amy Wang](#)...Wendy Stock, Richard Larson...James LaBelle, Justin Kline, Peter Riedell...Michael Bishop.

**Program:** Oral and Poster Abstracts

**Session:** 721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities II

**Time and Location:** Saturday, December 5, 2020: 12:00 PM–1:30 PM; Channel 23

[Barriers and Resident Attitudes Surrounding Care of Patients with Sickle Cell Disease](#)

**Result Type:** Paper

**Number:** 1569

**Presenter:** Daniela Anderson

Daniela Anderson...[Sharjeel Syed](#), [Jacobi Hines](#), [Nabil Baker](#).

**Program:** Oral and Poster Abstracts

**Session:** 901. Health Services Research—Non–Malignant Conditions: Poster I

**Time and Location:**

Saturday, December 5, 2020: 7:00 AM–3:30 PM; Poster Hall

[Real–World Validity of the Revised International Staging System in Multiple Myeloma By Race](#)

**Result Type:** Paper

**Number:** 1641

**Presenter:** Lucia Notardonato

L Notardonato...Brian Chiu, Benjamin Derman.

**Program:** Oral and Poster Abstracts

**Session:** 905. Outcomes Research—Malignant Conditions (Lymphoid Disease): Poster I

**Time and Location:** Saturday, December 5, 2020: 7:00 AM–3:30 PM; Poster Hall

[The Role of Structural Violence in Acute Myeloid Leukemia Outcomes](#)

**Result Type:** Paper

**Number:** 217

**Presenter:** Irum Khan

I Abraham...[Anand Patel](#)...I Khan.

**Program:** Oral and Poster Abstracts

**Session:** 906–Outcomes Research—Malignant Conditions (Myeloid Disease): Real World Management

# #ASH20

and Outcome

**Time and Location:** Saturday, December 5, 2020: 12:00 PM–1:30 PM; Channel 4

## Sunday, December 6, 2020

### [Loss of LKB1 / STK17 Facilitates Leukemic Progression of the Myeloproliferative Neoplasms](#)

**Result Type:** Paper

**Number:** 1

**Presenter:** Christian Marinaccio

C Marinaccio...**Sandeep Gurbuxani**...J Crispino.

**Program:** General Sessions

**Session:** Plenary Scientific Session

**Time and Location:** Sunday, December 6, 2020: 7:00 AM–9:00 AM; Channel 1

### [Thromboelastography in Evaluation of Hyperfibrinolysis: A Single Center Review](#)

**Result Type:** Paper

**Number:** 1792

**Presenter:** Timothy Carll

Timothy Carll, Geoffrey Wool.

**Program:** Oral and Poster Abstracts

**Session:** 322. Disorders of Coagulation or Fibrinolysis: Poster II

**Time and Location:** Sunday, December 6, 2020: 7:00 AM–3:30 PM; Poster Hall

### [D-Dimer As a Predictor of Thrombotic Events during Early Acute Lymphoblastic Leukemia Therapy](#)

**Result Type:** Paper

**Number:** 1901

**Presenter:** Daniela Anderson

Daniela Anderson...**Theodore Karrison, Wendy Stock.**

**Program:** Oral and Poster Abstracts

**Session:** 612. Acute Lymphoblastic Leukemia: Clinical Studies: Poster II

**Time and Location:** Sunday, December 6, 2020: 7:00 AM–3:30 PM; Poster Hall

### [Therapy-Related Myeloid Neoplasms in 108 Patients Following Radiation Therapy Only](#)

**Result Type:** Paper

**Number:** 1920

**Presenter:** Anand Patel

Anand Patel...**Michael Drazer, Lucy Godley, Michelle Le Beau, Richard Larson.**

**Program:** Oral and Poster Abstracts

**Session:** 613. Acute Myeloid Leukemia: Clinical Studies: Poster II

**Time and Location:** Sunday, December 6, 2020: 7:00 AM–3:30 PM; Poster Hall



# #ASH20

[Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia \(AML\) Patients on a Weekly Dosing Schedule of Vibecotamab \(XmAb14045\), a CD123 x CD3 T Cell-Engaging Bispecific Antibody: Initial Results of a Phase 1 Study](#)

**Result Type:** Paper

**Number:** 460

**Presenter:** Farhad Ravandi

F Ravandi...**Wendy Stock**...A Mims.

**Program:** Oral and Poster Abstracts

**Session:** 613. Acute Myeloid Leukemia: Potpourri of Potential Practice Changing Studies

**Time and Location:** Sunday, December 6, 2020: 2:00 PM–3:30 PM; Channel 12

[Molecular Landscape and Prognostic Impact of \*FLT3\* Internal Tandem Duplication Insertion Site in Acute Myeloid Leukemia \(AML\): Results from the Ratify Study \(Alliance 10603\)](#)

**Result Type:** Paper

**Number:** 391

**Presenter:** Frank Rücker

F Rücker...**Richard Larson**...K Dohner.

**Program:** Oral and Poster Abstracts

**Session:** 613. Acute Myeloid Leukemia: Molecular Mutations and Their Prognostic Implications

**Time and Location:** Sunday, December 6, 2020: 12:00 PM–1:30 PM; Channel 12

[Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with \*FLT3\* Mutations](#)

**Result Type:** Paper

**Number:** 1904

**Presenter:** Marina Konopleva

M Konopleva, **Michael Thirman**...A Wei.

**Program:** Oral and Poster Abstracts

**Session:** 613. Acute Myeloid Leukemia: Clinical Studies: Poster II

**Time and Location:** Sunday, December 6, 2020: 7:00 AM–3:30 PM; Poster Hall

[The First-in-Class Anti-CD47 Antibody Magrolimab Combined with Azacitidine Is Well-Tolerated and Effective in AML Patients: Phase 1b Results](#)

**Result Type:** Paper

**Number:** 330

**Presenter:** David Sallman

D Sallman...**Richard Larson**...N Daver.

**Program:** Oral and Poster Abstracts

**Session:** 613. Acute Myeloid Leukemia: Novel Therapies and Treatment Approaches

**Time and Location:** Sunday, December 6, 2020: 9:30 AM–11:00 AM; Channel 12

[R-CHOP Versus R-Bendamustine with or without Rituximab Maintenance in Newly Diagnosed Follicular Lymphoma Patients with High SUV at Baseline PET](#)

# #ASH20

**Result Type:** Paper

**Number:** 2041

**Presenter:** Patrizia Mondello

P Mondello...[Ajay Major](#)...G Salles.

**Program:** Oral and Poster Abstracts

**Session:** 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster II

**Time and Location:** Sunday, December 6, 2020: 7:00 AM–3:30 PM; Poster Hall

[Survival Varies By Age and Histology in Classical Hodgkin Lymphoma: A Report from the Children's Oncology Group](#)

**Result Type:** Paper

**Number:** 2072

**Presenter:** Justine Kahn

J Kahn...[Tara Henderson](#)...S Castellino.

**Program:** Oral and Poster Abstracts

**Session:** 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Poster II

**Time and Location:** Sunday, December 6, 2020: 7:00 AM–3:30 PM; Poster Hall

[Macrophage Activation By Dual PI3K- \$\delta\$ / \$\gamma\$  Inhibition Enhances Anti-CD47-Mediated Phagocytosis and Prolongs Survival in DLBCL](#)

**Result Type:** Paper

**Number:** 2087

**Presenter:** James Godfrey

[James Godfrey](#)...[Sonali Smith](#), [Justin Kline](#).

**Program:** Oral and Poster Abstracts

**Session:** 625. Lymphoma: Pre-Clinical—Chemotherapy and Biologic Agents: Poster II

**Time and Location:** Sunday, December 6, 2020: 7:00 AM–3:30 PM; Poster Hall

[Interim Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleuce \(Axi-Cel\) as First-Line Therapy in Patients \(Pts\) With High-Risk Large B Cell Lymphoma \(LBCL\)](#)

**Result Type:** Paper

**Number:** 405

**Presenter:** Sattva Neelapu

S Neelapu...[Peter Riedell](#)...J Chavez.

**Program:** Oral and Poster Abstracts

**Session:** 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: Updates and advances in bispecific antibody therapies and autologous CAR-T approaches

**Time and Location:** Sunday, December 6, 2020: 12:00 PM–1:30 PM; Channel 8

[Outcomes of Patients \(Pts\) in ZUMA-9, a Multicenter, Open-Label Study of Axicabtagene Ciloleuce \(Axi-Cel\) in Relapsed/Refractory Large B Cell Lymphoma \(R/R LBCL\) for Expanded Access and Commercial Out-of-Specification \(OOS\) Product](#)

# #ASH20

**Result Type:** Paper

**Number:** 2100

**Presenter:** Caron Jacobson

C Jacobson...**Peter Riedell**...S Neelapu.

**Program:** Oral and Poster Abstracts

**Session:** 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: Poster II

**Time and Location:** Sunday, December 6, 2020: 7:00 AM–3:30 PM; Poster Hall

## [CNS Prophylaxis during Front-Line Therapy in Aggressive Non-Hodgkin Lymphomas: Real-World Outcomes and Practice Patterns from 19 US Academic Institutions](#)

**Result Type:** Paper

**Number:** 478

**Presenter:** Victor Orellana-Noia

V Orellana-Noia...**Ajay Major**...C Portell.

**Program:** Oral and Poster Abstracts

**Session:** 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies: PCNSL Treatment and Prognosis and CNS Prophylaxis in High-Risk Aggressive Lymphomas

**Time and Location:** Sunday, December 6, 2020: 2:00 PM–3:30 PM; Channel 8

## [Real World \(RW\) Outcomes and Prognostication of Older Patients with Primary Central Nervous System Lymphoma \(PCNSL\) in the Contemporary Era](#)

**Result Type:** Paper

**Number:** 476

**Presenter:** Kevin David

K David...**Ajay Major**...**Sonali Smith**...A Evens.

**Program:** Oral and Poster Abstracts

**Session:** 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies: PCNSL Treatment and Prognosis and CNS Prophylaxis in High-Risk Aggressive Lymphomas

**Time and Location:** Sunday, December 6, 2020: 2:00 PM–3:30 PM; Channel 8

## [Potential Disease-Modifying Activity of Imetelstat Demonstrated By Reduction in Cytogenetically Abnormal Clones and Mutation Burden Leads to Clinical Benefits in Relapsed/Refractory Myelofibrosis Patients](#)

**Result Type:** Paper

**Number:** 346

**Presenter:** John Mascarenhas

J Mascarenhas...**Olatoyosi Odenike**...J Kiladjian.

**Program:** Oral and Poster Abstracts

**Session:** 634. Myeloproliferative Syndromes: Clinical: Translational Science in MPN— Hitting the Mark

**Time and Location:** Sunday, December 6, 2020: 9:30 AM–11:00 AM; Channel 15

# #ASH20

[Telomerase Activity, Telomere Length and hTERT Expression Correlate with Clinical Outcomes in Higher-Risk Myelofibrosis \(MF\) Relapsed/Refractory \(R/R\) to Janus Kinase Inhibitor Treated with Imetelstat](#)

**Result Type:** Paper

**Number:** 347

**Presenter:** John Mascarenhas

J Mascarenhas...**Olatoyosi Odenike**...J Kiladjian.

**Program:** Oral and Poster Abstracts

**Session:** 634. Myeloproliferative Syndromes: Clinical: Translational Science in MPN— Hitting the Mark

**Time and Location:** Sunday, December 6, 2020: 9:30 AM–11:00 AM; Channel 15

[Assessment of Minimal Residual Disease By Next-Generation Sequencing and Fluorodeoxyglucose-Positron Emission Tomography in Patients with Relapsed/Refractory Multiple Myeloma Treated with Venetoclax in Combination with Carfilzomib and Dexamethasone](#)

**Result Type:** Paper

**Number:** 2251

**Presenter:** Luciano Costa

L Costa...**Andrzej Jakubowiak**...F Davies.

**Program:** Oral and Poster Abstracts

**Session:** 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster II

**Time and Location:** Sunday, December 6, 2020: 7:00 AM–3:30 PM; Poster Hall

[Sustained Minimal Residual Disease \(MRD\) Negativity and Clinical Efficacy in Transplant-Ineligible \(TIE\) Newly Diagnosed Multiple Myeloma \(NDMM\) Patients \(Pts\) Treated with Daratumumab-Based Regimens: Analysis of Maia and Alcyone](#)

**Result Type:** Paper

**Number:** 2317

**Presenter:** Jesus San-Miguel

J San-Miguel...**Andrzej Jakubowiak**...N Bahlis.

**Program:** Oral and Poster Abstracts

**Session:** 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Poster II

**Time and Location:** Sunday, December 6, 2020: 7:00 AM–3:30 PM; Poster Hall

[Health-Related Quality of Life in the Cartitude-1 Study of Ciltacabtagene Autoleucl for Relapsed/Refractory Multiple Myeloma](#)

**Result Type:** Paper

**Number:** 2291

**Presenter:** Thomas Martin

T Martin...**Andrzej Jakubowiak**, S Jagannath.

**Program:** Oral and Poster Abstracts

**Session:** 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Poster II

**Time and Location:** Sunday, December 6, 2020: 7:00 AM–3:30 PM; Poster Hall

# #ASH20

[Aggressive Smoldering Curative Approach Evaluating Novel Therapies \(ASCENT\): A Phase 2 Trial of Induction, Consolidation and Maintenance in Subjects with High Risk Smoldering Multiple Myeloma \(SMM\): Initial Analysis of Safety Data](#)

**Result Type:** Paper

**Number:** 2285

**Presenter:** Shaji Kumar

S Kumar...**Andrzej Jakubowiak**...B Durie.

**Program:** Oral and Poster Abstracts

**Session:** 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Poster II

**Time and Location:** Sunday, December 6, 2020: 7:00 AM–3:30 PM; Poster Hall

[Creating a Variant Database for the American Society of Hematology By Consensus Variant Classification of Common Genes Associated with Hematologic Malignancies](#)

**Result Type:** Paper

**Number:** 360

**Presenter:** Niroshan Nadarajah

N Nadarajah...**Michelle Le Beau**...T Haferiach.

**Program:** Oral and Poster Abstracts

**Session:** 803. Emerging Diagnostic Tools and Techniques I

**Time and Location:** Sunday, December 6, 2020: 9:30 AM–11:00 AM; Channel 21

## Monday, December 7, 2020

[Identifying Potential Drug Targets for Sickle Cell Disease through Gene Expression and Pathway Analysis of GEO Data](#)

**Result Type:** Paper

**Number:** 2617

**Presenter:** Sharjeel Syed

[Sharjeel Syed](#)...D Hadley.

**Program:** Oral and Poster Abstracts

**Session:** 113. Hemoglobinopathies, Excluding Thalassemia—Basic and Translational Science: Poster III

**Time and Location:** Monday, December 7, 2020: 7:00 AM–3:30 PM; Poster Hall (Virtual Meeting)

[Transcriptional Control of HP1a By the RNA Binding Proteins RbmX/L1 Maintain Chromatin State in Myeloid Leukemia](#)

**Result Type:** Paper

**Number:** 523

**Presenter:** Diu Nguyen

D Nguyen...[Katerina Hoskova](#), [Meera Dhodapkar](#)...M Kharas.

**Program:** Oral and Poster Abstracts

**Session:** 603. Oncogenes and Tumor suppressors: Pre-clinical models and Novel Targets

**Time and Location:** December 7, 2020: 7:00 AM–8:30 AM; Channel 14 (Virtual Meeting)

# #ASH20

## [Expanding Use of a Modified Pediatric Intensive Regimen for Acute Lymphoblastic Leukemia \(ALL\) into an Older Adult Population: Feasibility and Efficacy Results](#)

**Result Type:** Paper

**Number:** 2796

**Presenter:** Anand Patel

Anand Patel...**Benjamin Derman**...**Hongtao Liu**, **Michael Thirman**, **Lucy Godley**, **Olatoyosi Odenike**, **Richard Larson**, **Wendy Stock**.

**Program:** Oral and Poster Abstracts

**Session:** 612. Acute Lymphoblastic Leukemia: Clinical Studies: Poster III

**Time and Location:** Monday, December 7, 2020: 7:00 AM–3:30 PM; Poster Hall (Virtual Meeting)

## [Single-Cell Analysis of the Classical Hodgkin Lymphoma Immune Environment Reveals a Clonally-Expanded CD8+ T Cell Population with a Cytotoxic Phenotype](#)

**Result Type:** Paper

**Number:** 594

**Presenter:** Jovian Yu

Jovian Yu...**James Godfrey**...**Sonali Smith**...**Justin Kline**.

**Program:** Oral and Poster Abstracts

**Session:** 622. Lymphoma Biology—Non-Genetic Studies: Microenvironment and Immune Response in Hodgkin Lymphoma

**Time and Location:** Monday, December 7, 2020: 9:00 AM–10:30 AM; Channel 8

## [Molecular Characteristics and Patterns of Progression of \*IDH2\*-Mutated, Philadelphia-Chromosome Negative, Advanced-Phase Myeloproliferative Neoplasms Treated with Enasidenib](#)

**Result Type:** Paper

**Number:** 2999

**Presenter:** Anand Patel

Anand Patel...**Hongtao Liu**...**Michael Thirman**...**Richard Larson**, **Wendy Stock**, **Jeremy Segal**, **Olatoyosi Odenike**.

**Program:** Oral and Poster Abstracts

**Session:** 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Poster III

**Time and Location:** Monday, December 7, 2020: 7:00 AM–3:30 PM; Poster Hall (Virtual Meeting)

## [EBV-Positive Primary CNS Lymphomas in Older Patients: Incidence, Characteristics, Tumor Pathology, and Outcomes across a Large Multicenter Cohort](#)

**Result Type:** Paper

**Number:** 3051

**Presenter:** Prashasti Agrawal

P Agrawal...**Sonali Smith**...**P Martin**.

**Program:** Oral and Poster Abstracts

**Session:** 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies: Poster III

**Time and Location:** Monday, December 7, 2020: 7:00 AM–3:30 PM; Poster Hall (Virtual Meeting)

# #ASH20

[Updated Follow-up of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated with Lisocabtagene Maraleucel in the Phase 1 Monotherapy Cohort of Transcend CLL 004, Including High-Risk and Ibrutinib-Treated Patients](#)

**Result Type:** Paper

**Number:** 546

**Presenter:** Tanya Siddiqi

T Siddiqi...**Peter Riedell**...W Wierda.

**Program:** Oral and Poster Abstracts

**Session:** 642. CLL: Therapy, excluding Transplantation II

**Time and Location:** Monday, December 7, 2020: 7:00 AM–8:30 AM; Channel 9 (Virtual Meeting)

[A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodysplastic Syndrome](#)

**Result Type:** Paper

**Number:** 3109

**Presenter:** Amer Zeidan

A Zeidan...**Olatoyosi Odenike**...G Garcia-Manero.

**Program:** Oral and Poster Abstracts

**Session:** 637. Myelodysplastic Syndromes—Clinical Studies: Poster III

**Time and Location:** Monday, December 7, 2020: 7:00 AM–3:30 PM; Poster Hall (Virtual Meeting)

[Cytokine Release Syndrome in Patients with Relapsed/Refractory Multiple Myeloma Treated with Ciltacabtagene Autoleucel in the Phase 1b/2 CARTITUDE-1 Study](#)

**Result Type:** Paper

**Number:** 3240

**Presenter:** Yi Lin

Y Lin...**Andrzej Jakubowiak**...S Jagannath.

**Program:** Oral and Poster Abstracts

**Session:** 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Poster III

**Time and Location:** Monday, December 7, 2020: 7:00 AM–3:30 PM; Poster Hall (Virtual Meeting)

[Daratumumab \(DARA\) Plus Lenalidomide, Bortezomib, and Dexamethasone \(RVd\) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma \(NDMM\): Updated Analysis of Griffin after 12 Months of Maintenance Therapy](#)

**Result Type:** Paper

**Number:** 549

**Presenter:** Jonathan Kaufman

J Kaufman...**Andrzej Jakubowiak**...P Voorhees.

**Program:** Oral and Poster Abstracts

**Session:** 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Initial Therapy

**Time and Location:** Monday, December 7, 2020: 7:00 AM–8:30 AM; Channel 10 (Virtual Meeting)

# #ASH20

## [Recovery of Ocular Events with Longer-Term Follow-up in the DREAMMM-2 Study of Single-Agent Belantamab Mafodotin \(Belamaf\) in Patients with Relapsed or Refractory Multiple Myeloma \(RRMM\)](#)

**Result Type:** Paper

**Number:** 3224

**Presenter:** Sagar Lonial

S Lonial...**Andrzej Jakubowiak**.

**Program:** Oral and Poster Abstracts

**Session:** 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Poster III

**Time and Location:** Monday, December 7, 2020: 7:00 AM–3:30 PM; Poster Hall (Virtual Meeting)

## [Outcomes of Patients with Relapsed Mantle Cell Lymphoma Treated with Venetoclax: A Multicenter Retrospective Analysis](#)

**Result Type:** Paper

**Number:** 2953

**Presenter:** Yazeed Sawalha

Y Sawalha...**Peter Riedell**...J Cohen.

**Program:** Oral and Poster Abstracts

**Session:** 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster III

**Time and Location:** Monday, December 7, 2020: 7:00 AM–3:30 PM; Poster Hall (Virtual Meeting)

## [Initial Treatment with Lenalidomide Plus Rituximab for Mantle Cell Lymphoma \(MCL\): 7-Year Analysis from a Multi-Center Phase II Study](#)

**Result Type:** Paper

**Number:** 704

**Presenter:** Samuel Yamshon

S Yamshon...**Sonali Smith**...J Ruan.

**Program:** Oral and Poster Abstracts

**Session:** 623. Mantle Cell and Indolent B-Cell Lymphoma – CAR-T and immunotherapy clinical studies

**Time and Location:** Monday, December 7, 2020: 1:30 PM–3:00 PM; Channel 7 (Virtual Meeting)

## [Enasidenib \(ENA\) Monotherapy with Addition of Azacitidine in Non-Responders Is Effective in Older Patients with Newly Diagnosed IDH2 Mutated Acute Myeloid Leukemia \(AML\): A Completed Phase 2/1b Sub-Study of the Beat AML Master Trial](#)

**Result Type:** Paper

**Number:** 636

**Presenter:** Eytan Stein

E Stein...**Wendy Stock**...A Mims.

**Program:** Oral and Poster Abstracts

**Session:** 615. Acute Myeloid Leukemia: Commercially Available Therapy, excluding Transplantation: Commercially Available Therapy, excluding Transplantation II

**Time and Location:** Monday, December 7, 2020: 11:30 AM–1:00 PM; Channel 12 (Virtual Meeting)



# #ASH20

## [Combined Inhibition of CXCR4 Signaling and System \$x\_c^-\$ Transporter Activity Induces Synthetic Lethality in T-ALL Cells By Suppressing Gsh and Inducing Ferroptosis](#)

**Result Type:** Paper

**Number:** 695

**Presenter:** Jun Xia

J Xia...[Matthew Jotte](#)...D Link.

**Program:** Oral and Poster Abstracts

**Session:** 618. Acute Lymphoblastic Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis I

**Time and Location:** Monday, December 7, 2020: 1:30 PM–3:00 PM; Channel 13 (Virtual Meeting)

## [SWOG S1826: A Phase III, Randomized Study of Nivolumab Plus AVD or Brentuximab Vedotin Plus AVD in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma](#)

**Result Type:** Paper

**Number:** 2969

**Presenter:** Alex Herrera

A Herrera...[Sonali Smith](#), J Friedberg.

**Program:** Oral and Poster Abstracts

**Session:** 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Poster III

**Time and Location:** Monday, December 7, 2020: 7:00 AM–3:30 PM; Poster Hall

## [Treatment with Imetelstat Improves Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in Patients with Relapsed or Refractory Higher-Risk Myelofibrosis](#)

**Result Type:** Paper

**Number:** 3088

**Presenter:** Jean-Jacques Kiladjian

J Kiladjian...[Olatoyosi Odenike](#)...A Vannucchi.

**Program:** Oral and Poster Abstracts

**Session:** 634. Myeloproliferative Syndromes: Clinical: Poster III

**Time and Location:** Monday, December 7, 2020: 7:00 AM–3:30 PM; Poster Hall

## [Imetelstat Treatment Results in Clinical Benefits, Including Improved Overall Survival, in Patients with Higher-Risk Triple-Negative Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitors \(JAKi\)](#)

**Result Type:** Paper

**Number:** 3084

**Presenter:** Jean-Jacques Kiladjian

J Kiladjian...[Olatoyosi Odenike](#)...A Vannucchi.

**Program:** Oral and Poster Abstracts

**Session:** 634. Myeloproliferative Syndromes: Clinical: Poster III

**Time and Location:** Monday, December 7, 2020: 7:00 AM–3:30 PM; Poster Hall

## [Safety, Efficacy, and Patient-Reported Outcomes of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome: A Phase 1b Study](#)

# #ASH20

**Result Type:** Paper

**Number:** 656

**Presenter:** Jacqueline Garcia

J Garcia...**Olatoyosi Odenike**...G Garcia-Manero.

**Program:** Oral and Poster Abstracts

**Session:** 637. Myelodysplastic Syndromes—Clinical Studies: Treatment of Higher Risk Myelodysplastic syndromes

**Time and Location:** Monday, December 7, 2020: 11:30 AM–1:00 PM; Channel 15 (Virtual Meeting)

[Phase 1 Study of CART-Ddbcm, a CAR-T Therapy Utilizing a Novel Synthetic Binding Domain for the Treatment of Subjects with Relapsed and Refractory Multiple Myeloma](#)

**Result Type:** Paper

**Number:** 3199

**Presenter:** Matthew Frigault

M Frigault, **Michael Bishop**...M Maus.

**Program:** Oral and Poster Abstracts

**Session:** 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Poster III

**Time and Location:** Monday, December 7, 2020: 7:00 AM–3:30 PM; Poster Hall (Virtual Meeting)

[Preliminary Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Subcutaneously \(SC\) Administered PF-06863135, a B-Cell Maturation Antigen \(BCMA\)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma \(RRMM\)](#)

**Result Type:** Paper

**Number:** 3206

**Presenter:** Alexander Lesokhin

A Lesokhin...**Andrzej Jakubowiak**...N Raje.

**Program:** Oral and Poster Abstracts

**Session:** 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Poster III

**Time and Location:** Monday, December 7, 2020: 7:00 AM–3:30 PM; Poster Hall (Virtual Meeting)

[Assessing the Feasibility and Limitations of Cultured Skin Fibroblasts for Germline Genetic Testing in Hematologic Disorders](#)

**Result Type:** Paper

**Number:** 3385

**Presenter:** Lia DeRoin

Lia DeRoin...**Lucy Godley, Jeremy Segal**...J Churpek.

**Program:** Oral and Poster Abstracts

**Session:** 803. Emerging Diagnostic Tools and Techniques: Poster III

**Time and Location:** Monday, December 7, 2020: 7:00 AM–3:30 PM; Poster Hall (Virtual Meeting)

[Early Assessment of Treatment Response in Acute Myeloid Leukemia Using FLT PET/CT Imaging: A Trial of the ECOG-ACRIN Cancer Research Group \(EAI141\)](#)

# #ASH20

**Result Type:** Paper

**Number:** 3380

**Presenter:** Ryan Mattison

R Jeraj...**Daniel Arber**...D Mankoff.

**Program:** Oral and Poster Abstracts

**Session:** 803. Emerging Diagnostic Tools and Techniques: Poster III

**Time and Location:** Monday, December 7, 2020: 7:00 AM–3:30 PM; Poster Hall (Virtual Meeting)